Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Arca Biopharma: Heart Disease Drug Looks Promising
- Heart failure has always been one of the predominant fatal human conditions, therefore this week I will be focusing on ARCA Biopharma ABIO, which has developed a highly successful treatment. The broad world market for this drug is truly spectacular. by Michael Catalin Vlaicu
- External links 2009-05-12
- INVO Bioscience: Giving Birth to a Profitable Company
- INVO BioScience Inc (Public, OTC:IVOB) The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Eric Sebastien. He is an entrepreneur with solid investment experience totalling fifteen years, and specializes in the small cap bio-tech field. by Michael Catalin Vlaicu
- External links 2009-08-23
- Javelin Pharmaceuticals: Pain for Pleasure
- By guest author Nicholas DeCesare, a highly respected investor and journalist within the biopharma realm. Take one look at a chart of Javelin Pharmaceuticals JAV over the past six months and you will see a stock that has doubled in price but still sits only around $2.00 per...
- External links 2009-08-06
- Waking Up to Somaxon Pharmaceuticals
- Below we profile one of the most promising biomedical pharmaceutical company involved with a PDUFA with regards to a drug which could quite possibly revolutionize the treatment for insomnia, a condition affecting over 70 million Americans. Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) has been making waves these past few months as investors...
- External links 2009-07-22
- Elan Corporation: Shares Seem Undervalued
- Elan Corporation ELN About Elan Corporation, plc Elan is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan’s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT)....
- External links 2009-07-10
- TerreStar Corp: Sky High Potential
- With the recent launching of TerreStar-1, TerraStar Corporation TSTR looks to break through and become a leader in the communications industry. AT&T Mobility T along with TerreStar Corporation will market a hybrid prototype terrestrial/satellite hand set yet this year. The technology will allow the new hand set to operate on...
- External links 2009-07-10
- Why Access Pharmaceutical's MuGard Will Be Successful
- Many investors have raised concerns with regards to Access Pharmaceuticals (ACCP.OB) being on the OTC. Indeed more than half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate investor demand. They will reach out...
- External links 2009-07-06
- BioDelivery Sciences: More than a One Drug Company
- Continuing with the trend of pre-FDA decision BioPharma companies, StocksHaven Investments takes a closer look at BioDelivery Sciences BDSI, which hopes its product Onsolis will stride past approval and make its way on to shelves world-wide. About BDSI: BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that...
- External links 2009-06-14
- Access Pharmaceuticals: Gaining Momentum
- Access Pharmaceuticals (ACCP.OB), a once struggling and troubled company, Access has put these issues behind them and is emerging as one of the top undervalued players in the BioPharma industry. Not only does this company have products which target a large and extensive market, but they are also implementing solid...
- External links 2009-06-11
- Hemispherx's Ampligen: Fact vs. Fiction
- Much to the delight of Hemispherx BioPharma individual and institutional investors, a reader and follower of StocksHaven Investments has identified several key points which have been raised recently, decyphering the fact from fiction. The following article has been submitted by an investor named Nick DeCesare. After...
- External links 2009-06-09
- Hemispherx's Ampligen Also Combats Avian Flu
- With the majority of the focus being placed on on the current pending FDA approval regarding (AMEX:HEB) Hemispherx’s Ampligen, StocksHaven Investments would like to shift the focus to the drug’s ability to help treat the potential outbreak of H5N1. Overview of H5N1 by Michael Catalin Vlaicu
- External links 2009-06-04
- CytRx: Technical Breakout Imminent
- Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation CYTR. Shares of the company finished trading during 11/20/09 at $1.35 per share, up 20.18% from the opening bell on heavy buying pressure. As of 11/18/09, the biopharmaceutical company announced plans to initiate an...
- External links 2009-11-23
- << Previous
- page 1 of 1
- Next >>
Presented by the Premiere Rewards Gold Card from American Express